• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Provident Financial Services Inc PFS

Last Price$20.29Day Change (%)0.84%
Open Price$20.14Day Change ($)0.17
Day Range20.14–20.3852-Week Range17.71–21.20

As of Wed 5/25/2016 2:22:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer

    ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer

  2. Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients

    Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients

  3. Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

    Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

  4. Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine

    Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine

  5. FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

    FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

  6. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

  7. Reasons for Optimism

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  8. Forward-Looking Broad-Market Investing

    Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, Distributor. An investment in the Funds is subject to ...

  9. What’s Wrong With Indexes?

    To the extent that this content includes references to securities, those references do not constitute an offer or solicitation to buy, sell or hold such security. AdvisorShares is a sponsor of actively managed exchange-traded funds (ETFs) and holds positions in all of its ETFs. This document should ...

  10. Danger: A Bond Cliff Looms

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.